Recently, Fortune (Chinese edition) released its "China's 40 Under 40 Business Elite" list. Zhu Pui, CEO of Efung Capital, was honored on Fortune China's 2025 "40 Under 40" Most Promising Business Elite list, showcasing the forward-looking vision and business acumen of the younger generation of entrepreneurs.
This year's list continues the dual-track selection mechanism from previous years, featuring both the "China's 40 Under 40 Business Elite" list and the "China's 40 Under 40 Most Promising Business Elite" list. The former recognizes the most influential young leaders in China today; the latter honors the most promising innovators across various industries.
As the AI representative on this year's list, Liang Wenfeng, Founder and CEO of DeepSeek, stood out prominently, demonstrating China's innovative strength in the field of artificial intelligence. The DeepSeek he founded has become a flagship product of Chinese AI, participating in the global wave of AI competition. Its performance on tasks such as mathematics, coding, and natural language reasoning is comparable to OpenAI o1, yet its training cost is only one-twentieth that of the latter.
Complementing this achievement is the outstanding performance of Efung Capital CEO Zhu Pui in the field of biopharmaceutical investment. As a professional biopharmaceutical investor, Zhu Pui has consistently adhered to the mission of "improving quality of life and creating value," employing deep industry research as a guide for project selection and making full-industry-chain investments in biopharmaceutical enterprises across all stages. Over the past few years, Zhu Pui has initiated and deeply participated in the investment and exit of over a hundred high-profile projects, including Obio Technology, Asieris Pharmaceuticals, and Harbour BioMed, forming a complete closed loop from early-stage incubation to commercial exit, successfully helping multiple innovative drug projects achieve the leap from laboratory to international markets. His inclusion on the Fortune list serves as authoritative recognition of his dual capabilities—"scientific research insight + commercial execution."
At the starting point of a new development stage, China's young generation of business leaders are driving industrial upgrading and economic transformation with more open thinking and stronger execution. Their business practices are not merely microcosms of personal endeavor but will become vivid footnotes to the rise of China's innovative power.